Business Wire

TECKRO

29.9.2021 15:06:05 CEST | Business Wire | Press release

Share
Teckro Launches Next-Generation Clinical Trial Mobile Platform, Giving Site Staff Faster Answers in Fewer Clicks

Teckro, the creator of the only clinical trials platform that facilitates collaboration and real-time decision-making between and among stakeholders, announces new product capabilities to accelerate site adoption of modern trial practices, making communication even easier at the point of care. A next-generation mobile app gives investigators and site staff answers in fewer clicks, while platform enhancements will result in new studies operational on Teckro in half the time.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210929005472/en/

Toward its vision of engaging every physician in clinical research, Teckro also unveils its “Teckro Powered” site program to establish a community of research sites ready to advance the industry and help shape future product requirements. Today, more than 23,000 research sites around the world rely on the Teckro platform for clinical trials in all therapeutic areas.

“With a critical mass of sites using Teckro, we deepen our commitment to a simple, site-driven experience that allows physicians to easily engage in research without compromising time caring for patients,” says Teckro CEO Gary Hughes. “Sponsors can ease the complexity of clinical trials with a frictionless way to communicate with sites, including when investigators can receive direct guidance from study experts at the point of care.”

First-Of-Its-Kind Site Program: Teckro Powered

“Teckro Powered” is a novel program open to any research site. The program includes a dedicated sandbox to preview Teckro capabilities and input into future requirements. In addition with the program, sites and site networks can:

  • Build a technology-ready brand. Teckro Powered sites are technically savvy. Designated with a program badge on their websites and social media platforms, sites can use this to differentiate themselves and build their reputations as “sites of choice” for sponsors.
  • Expand physician participation in research. Behind the Teckro Powered program is a community of research sites to open a new way to collaborate and advance the industry. With the strength of a Teckro Powered community, the goal is to encourage more physicians to participate in clinical trials, reaching broader, diverse patient populations.
  • Limit impact of staff turnover. Teckro Powered is a way for sites to mitigate disruption from staff turnover. With study resources conveniently hosted in Teckro and accessible from a smartphone, sites can simplify new study member onboarding. A central source for content, communication and collaboration reduces the time to train new staff over the course of a trial.

“The Teckro Powered program fills a gap in the industry,” says Director of Site Strategy Silvina Baudino. “Working with sites for almost 20 years, I know how challenging clinical research can be. Teckro is dedicated to the site experience, which you see in both the new product capabilities and the investment in the Teckro Powered program. We are creating a way for sites to differentiate themselves and participate in a community of research sites.”

Maximizing Sponsor-Site Collaboration

Teckro’s latest platform enhancements go toward solving gaps in communication and easing the burden on site staff. A hub for study content and communication, the new Teckro capabilities include:

  • Next-generation mobile application. The streamlined app provides a simple, mobile-first user experience to support point of care decisions. Based on deep user research, the new mobile application is optimally designed for clinical trial answers in just a couple of clicks. The new Teckro mobile app is now available in the app stores for Apple and Android smartphones.
  • Diverse experts on demand . Teckro is expanding its communication to support more granular groups of experts for different types of site queries. Real-time guidance from those best suited to provide answers eliminates the need for a “switchboard” or for study monitors to operate as a go-between. The feature will be available in the fourth quarter.
  • Increased speed and scale. Underlying platform improvements mean new studies can be added in half the time. This allows sponsors to standardize on Teckro as a resource for their sites to access current study content and communications across trials.

Meet Teckro at the Global Site Solution Summit
Teckro is a sponsor at the upcoming Global Site Solution Summit (October 1-3). Visit us at Booth 716 to see a demo and talk with our experts. You can also request a meeting with Silvina Baudino (Teckro director of site strategy) or Malia Lewin (Teckro global head of strategy) by completing the form on our event page . Silvina will also participate as a panelist in the breakout session “It's Not You, It's Me: How to Manage Long-Term Partnerships” on both October 2 at 1:30 p.m. and October 3 at 9 a.m.

About Teckro
Recognized as one of the fastest growing clinical trial start-ups, Teckro transforms the study protocol into a hub of communication and collaboration. It’s a digital platform that connects all study stakeholders with the knowledge they need, when they need it. Thousands of investigators and more than 23,000 sites around the world rely on Teckro to execute clinical trials from biopharma sponsors, including 12 out of the Top 20 pharma companies. Teckro supports all therapeutic areas, all phases, and any trial format ranging from traditional in-clinic, decentralized clinical trials, or a hybrid approach.

More Information

Link:

ClickThru

Social Media:

https://www.facebook.com/teckroofficial/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release

Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European

Digital Reef Turns to Vertical Farming to Reduce Data Centre Footprint in Partnership With Elevate Farms and Xange.com to Provide Digital Measurement, Reporting and Verification of Project's Environmental Impact Within the Reef Origin Ecosystem23.10.2026 13:12:00 CEST | Press release

The collaboration leverages Elevate Farms’ proprietary vertical farming technology reducing water consumption, land usage and carbon emissions. Elevate Farms Inc. and Digital Reef Ltd partnership supports mitigating environmental impact of global data centre expansion establishing a framework for Digital Reef’s infrastructure pipeline to support and utilize environmental assets generated by Elevate Farms' high-yield, closed-loop vertical farming operations. Traditional agriculture supply chains are replaced with optimized indoor facilities significantly reducing food production carbon emissions, water waste and local land constraints. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022393352/en/ Elevate Farms technology offers part of the solution to climate impact isolating food production from traditional agricultural farming variables saving over 95% of standard water requirements and significantly reducing farmland req

SLB Announces Third-Quarter 2026 Results23.10.2026 12:50:00 CEST | Press release

Revenue of $9.45 billion increased 5% sequentially and 6% year on year GAAP EPS of $0.49 decreased 6% sequentially and 2% year on year EPS, excluding charges and credits, of $0.64 increased 16% sequentially and decreased 7% year on year Net income attributable to SLB of $735 million decreased 6% sequentially and 1% year on year Adjusted EBITDA of $2.07 billion increased 9% sequentially and was essentially flat year on year Cash flow from operations was $1.51 billion and free cash flow was $828 million Board approved quarterly cash dividend of $0.295 per share SLB (NYSE: SLB) today announced results for the third-quarter 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261021694458/en/ The exterior of the SLB headquarters in Houston, Texas. Third-Quarter Results(Stated in millions, except per share amounts)Three Months EndedChangeSept. 30, 2026Jun. 30, 2026Sept. 30, 2025SequentialYear-on-yearRevenue $9,449 $8,972 $8,928 5

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye